OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
FDA's Evans Reviews Causes of Warnings and Recalls
In the Oct. 25 keynote address of the Institute of Validation Technology'sValidation Week conference in Philadelphia, PA, Kristen Evans presented the early statistical analyses of the US Food and Drug Administration's regulatory actions for Fiscal Year 2005. Evans leads the Guidance andPolicy Team in the Division of Manufacturing and Product Quality inFDA's Center for Drug Evaluation and Research (IVT is owned byAdvanstar Communications, which publishes Pharmaceutical Technology.)
While warning that some of the results are preliminary and may besubject to some refinement, Evans did highlight several trends:
Warning Letters and GMP Citations.The analysis of Warning Letters and GMP citations (see Table I),shortcomings in the performance of the quality control unit (21 CFR 211.22) and in testing and release for distribution (21 CFR211.165) jumped up in frequency to share first place among categoriesfor cited deficiencies. On the other hand, two previously leadingcauses of citations dropped out of the top ten altogether in 2005:lapses in production record review and failure investigations (21 CFR211.192), historically the second- or third-ranking citation, hasdropped to number 17 on the list. And poor personnel qualification (21CFR 211.25), has dropped to about number 20.
Recalls. The analysisof 354 product recalls in fiscal year 2005 (see Tables III and IV) showed thatCGMP deviations are increasingly the most common cause of productrecalls. Though CGMP deviations have historically been the primaryreason for recalls, accounting for 14.5% of the 3619 recalls from 1987through 2004, they caused 40.7% of the recalls in 2005. Thesecond-ranking cause of product recalls is failure of USP dissolutiontests, accounting for 12.9% of historical recalls and 15.5% of recallsin 2005. Evans noted the current discussion of the USP dissolution testitself, and referred to the Agency's scientific advisory board meetingon the topic this week.
Rank 2004 | Rank 2005 | Subpart | Title |
1 | 3 | 211.100 | Written Production Procedures |
2 | 4 | 211.67 | Equipment Cleaning and Maintenance |
3 | 1 | 211.22 | Responsibilities of Quality Control Unit |
4 | 6 | 211.113 | Control of Microbiological Contents |
5 | 8 | 211.160 | Laboratory General Requirements |
6 | 1 | 211.165 | Testing and Release for Distribution |
7 | 4 | 211.166 | Stability Testing |
8 | 8 | 211.188 | Production and Control Records |
9 | 9 | 211.84 | Testing and Approval or Rejection of Components, Drug ProductContainers, and Closures |
10 | 17 | 211.192 | Production Record Review (Failure Investigations) |
11 | 6 | 211.42 | Design and Construction Features |
12 | 13 | 211.198 | Complaint Files |
12 | 20 | 211.25 | Personnel Qualifications |
Rank | Subpart | Title |
1 | 211.22 (d) | Responsibilities of Quality Control Unit |
2 | 211.110 (a) | In-Process Sampling and Testing |
3 | 211.100 (b) | Adherence to Production Procedures |
4 | 211.100 (a) | Production Procedures (Validation) |
5 | 211.192 | Batch Review (Investigations) |
6 | 211.25 (a) | Personnel Qualification |
7 | 211.160 (b) | Laboratory Controls |
8 | 211.165 (a) | Testing and Release |
9 | 211.188 | Batch Record Review |
10 | 211.68 (a) | Equipment Maintenance |
N | % | Reason |
354 | 100% | Total |
144 | 40.7% | CGMP Deviation |
55 | 15.5% | Failed USP Dissolution Test Requirements |
30 | 8.5% | Microbial Contamination of Nonsterile Products |
25 | 7.1% | Lack of Efficacy |
24 | 6.8% | Labeling Error |
18 | 5.1% | Impurities and Degradation |
17 | 4.8% | Lack of Assurance of Sterility |
16 | 4.5% | Product Lacks Stability |
13 | 3.7% | Misbranded: Promotional Literature with Unapproved Claims |
12 | 3.4% | Subpotent |
N | % | Reason |
3619 | 100% | Total |
523 | 14.5% | CGMP Deviation |
467 | 12.9% | Failed USP Dissolution Test Requirements |
454 | 12.5% | Subpotent (Single-Ingredient Drug) |
414 | 11.4% | Lack of Assurance of Bioequivalence |
379 | 10.5% | Lack of Assurance of Sterility |
317 | 8.8% | Penicillin Cross-Contamination |
311 | 8.6% | Stability Data Do Not Support Expiration Date |
310 | 8.6% | Labeling: Label Mix-Up |
241 | 6.7% | Microbial Contamination of Nonsterile Products |
203 | 5.6% | Marketed Without an Approved NDA or ANDA |